CIK 0001671858 · Non-accelerated filer<br>Smaller reporting company
ARS Pharmaceuticals, Inc.
Sign in to watch- Ticker
- SPRY
- Exchange
- Nasdaq
- Industry
- Pharmaceutical Preparations
- FY end
- Dec 31
- Incorporated
- DE
- Entity type
- operating
- EIN
- 811489190
- Phone
- 858-771-9307
- Business address
- 11682 EL CAMINO REAL, SUITE 300, SAN DIEGO, CA, 92130
- Former names
- Silverback Therapeutics, Inc.
- Open-market buys, last 90 days
- $0
- in 0 filings
- Open-market sales, last 90 days
- $0
- in 0 filings
Shares bought or sold at a price by officers, directors and 10% owners (Form 4 codes P and S). Grants, option exercises and tax withholding aren't counted.
Reading 100 more Form 4s from the SEC; this list fills in as they're read.
| Date | Insider | Transaction | Shares | Price | Value | Owned after |
|---|---|---|---|---|---|---|
| 2025-05-20 | Fitzpatrick Alexander A Chief Legal Officer | Option exercise · Stock Option (Right to Buy) | −100,000 | 200,000 | ||
| 2025-05-20 | SAUNDERS BRENT L Director | Option exercise | +120,000 | $1.01 | $121K | 120,000 |
| 2025-05-20 | SAUNDERS BRENT L Director | Sale | −120,000 | $14.25 | $1.7M | 0 |
| 2025-05-20 | SAUNDERS BRENT L Director | Option exercise · Stock Option (Right to Buy) | −120,000 | 470,950 | ||
| 2025-05-20 | Scott Kathleen D. Chief Financial Officer | Option exercise | +50,000 | $1.50 | $75K | 57,424 |
| 2025-05-20 | Scott Kathleen D. Chief Financial Officer | Sale | −50,000 | $14.10 | $705K | 7,424 |
| 2025-05-20 | Scott Kathleen D. Chief Financial Officer | Option exercise · Stock Option (Right to Buy) | −50,000 | 752,330 | ||
| 2025-04-07 | Shawver Laura Director | Option exercise 10b5-1 | +22,509 | $4.85 | $109K | 232,855 |
| 2025-04-07 | Shawver Laura Director | Option exercise 10b5-1 | +27,493 | $4.85 | $133K | 260,348 |
| 2025-04-07 | Shawver Laura Director | Sale 10b5-1 | −50,002 | $12.30 | $615K | 210,346 |
| 2025-04-07 | Shawver Laura Director | Option exercise · Stock Option (Right to Buy) 10b5-1 | −22,509 | 51,555 | ||
| 2025-04-07 | Shawver Laura Director | Option exercise · Stock Option (Right to Buy) 10b5-1 | −27,493 | 24,062 | ||
| 2025-03-20 | Karas Eric Chief Commercial Officer | Option exercise 10b5-1 | +10,000 | $1.50 | $15K | 17,696 |
| 2025-03-20 | Karas Eric Chief Commercial Officer | Sale 10b5-1 | −10,000 | $14.00 | $140K | 7,696 |
| 2025-03-20 | Karas Eric Chief Commercial Officer | Option exercise · Stock Option (Right to Buy) 10b5-1 | −10,000 | 574,588 | ||
| 2025-03-06 | Shawver Laura Director | Option exercise 10b5-1 | +49,600 | $4.85 | $241K | 259,946 |
| 2025-03-06 | Shawver Laura Director | Sale 10b5-1 | −49,600 | $11.21 | $556K | 210,346 |
| 2025-03-06 | Shawver Laura Director | Option exercise · Stock Option (Right to Buy) 10b5-1 | −49,600 | 74,064 | ||
| 2025-03-05 | Shawver Laura Director | Option exercise 10b5-1 | +400 | $4.85 | $2K | 210,746 |
| 2025-03-05 | Shawver Laura Director | Sale 10b5-1 | −400 | $11.00 | $4K | 210,346 |
Page 4 of 14 · 267 trades